What is Jumpcode Genomics?
Jumpcode Genomics operates at the intersection of molecular biology and data science, specializing in the enhancement of NGS data usability. The company provides a sophisticated suite of tools, including programmable endonuclease enzymes and specialized depletion kits, designed to optimize single-cell analysis, microbiome characterization, and whole transcriptome profiling. By effectively filtering out uninformative sequenced molecules, Jumpcode Genomics empowers researchers at academic and clinical institutions to extract higher-fidelity insights from their genomic data. This technological edge positions the company as a critical infrastructure provider for the future of precision medicine and infectious disease diagnostics.
How much funding has Jumpcode Genomics raised?
Jumpcode Genomics has raised a total of $24.5M across 2 funding rounds:
Series A
$3.5M
Series B
$21M
Series A (2018): $3.5M, investors not publicly disclosed
Series B (2021): $21M led by LYZZ Capital Advisors, Arboretum Ventures LLC, and Baird Capital
Key Investors in Jumpcode Genomics
Baird Capital
Baird Capital is a private equity and venture capital firm that invests in founder-led B2B tech and services companies globally, providing operational support and expertise to foster growth.
Arboretum Ventures LLC
Arboretum Ventures is a healthcare-focused venture capital firm that partners with entrepreneurs to build transformative companies in the medical device, life science, and healthcare IT sectors.
LYZZ Capital Advisors
LYZZ Capital Advisors is an investment firm specializing in strategic capital allocation for high-growth life sciences and biotechnology enterprises.
What's next for Jumpcode Genomics?
With the infusion of capital from its latest financing round, Jumpcode Genomics is well-positioned to accelerate its commercial expansion and R&D initiatives. The company is expected to focus on broadening its product portfolio to address emerging challenges in high-throughput sequencing. As the demand for actionable genomic data continues to rise, Jumpcode's strategic roadmap likely involves deepening its market penetration within the global research community and forging new partnerships to integrate its depletion technologies into standard laboratory workflows. This phase of growth will be instrumental in cementing the company's status as a leader in the genomics data optimization market.
See full Jumpcode Genomics company page
